Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.65 USD | -1.94% | -2.35% | -4.90% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 16.49M | Capitalization | 491M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -110M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 23.5 x |
P/E ratio 2024 * |
-3.91
x | P/E ratio 2025 * |
-4.97
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | -1.94% | ||
1 week | -2.35% | ||
Current month | -1.77% | ||
1 month | -2.35% | ||
3 months | -10.38% | ||
6 months | +22.76% | ||
Current year | -4.90% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +4.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 11.65 | -1.94% | 298,729 |
24-04-16 | 11.88 | +1.19% | 489,733 |
24-04-15 | 11.74 | -1.26% | 313,461 |
24-04-12 | 11.89 | -1.74% | 237,892 |
24-04-11 | 12.1 | +1.42% | 312,126 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.90% | 501M | |
-5.54% | 85.08B | |
+2.11% | 40.14B | |
-25.74% | 28.37B | |
+51.96% | 24.07B | |
-6.17% | 17.24B | |
-31.09% | 13.85B | |
-6.58% | 12.29B | |
-16.04% | 11.95B | |
-4.19% | 8.02B |
- Stock Market
- Equities
- KALV Stock